Generic Name: atezolizumab
Drug Class: Immunotherapy Medications
Approval Status: Approved
Generic Version Available: No
Tecentriq is a checkpoint inhibitor approved for the treatment of advanced or metastatic bladder (urothelial) cancer, metastatic non-small-cell lung cancer, extensive-stage small-cell lung cancer, metastatic liver cancer and inoperable or metastatic melanoma.
Tecentriq is a monoclonal antibody used in cancer immunotherapy. It is a checkpoint inhibitor that blocks the PD-L1 protein on cancer cells or immune cells in tumors. PD-1 is an immune checkpoint on T cells that plays a role in regulating immune function. Some tumors can hijack PD-1 to turn off immune responses against them. Drugs that block the interaction between PD-1 and PD-L1, its binding partner, can release the brakes and restore T-cell activity.
Clinical trials showed that Tecentriq slows progression of bladder cancer (IMvigor210 study), non-small-cell lung cancer (IMpower 110, IMpower130 and IMpower 150), small-cell lung cancer (IMpower133), breast cancer (IMpassion130), hepatocellular carcinoma, the most common type of liver cancer (IMbrave150) and melanoma with BRAF V600 mutation (IMspire150). It was first approved in 2016.
Tecentriq is administered as an intravenous infusion. The dosing and scheduled depends on the type of cancer and the other medications in a combination regimen.
Common side effects include fatigue, decreased appetite, muscle pain, cough and shortness of breath. Checkpoint inhibitors can cause an overactive immune response that harms healthy organs and tissues. Serious immune-mediated side effects can affect almost any organ including the lungs, liver, kidneys, intestines, skin and hormone-producing endocrine glands.
For More Info: https://www.tecentriq.com/
Co-Pay Program Info: https://www.tecentriq.com/nsclc/patient-support/financial-assistance.html
Patient Assistance Program Info: https://www.tecentriq.com/nsclc/patient-support/financial-assistance.html
Last Reviewed: September 7, 2021